Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

STAAR Surgical Company

STAANASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 18, 2026Accepted Aug 18, 2026, 4:03 PM EDTFiling CIK 718937Accession 0001325697-26-000011
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-08-14
Issuer
STAAR SURGICAL CO
Issuer CIK
0000718937
Trading symbol
STAA

Reporting owner 1

Name
ANDREWS DEBORAH J
Reporting owner CIK
0001325697
Relationship
Officer
Officer title
Chief Financial Officer & EVP
Address
25510 COMMERCENTRE DRIVE, LAKE FOREST, CA, 92630

Non-derivative transactions

Non-derivative transactions · 2 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-08-14M · Form 45,233A041,452D
Common Stock2026-08-14F · Form 42,662[F1]D26.1838,910D
Table key
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3
A
Acquired
D
Direct
F · Form 4
Securities delivered or withheld for exercise price or tax liability under Rule 16b-3

Derivative transactions

Derivative transactions · 4 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Restricted Stock Units0[F2]2026-08-14A · Form 44,975A0[F3][F4]Common Stock4,9754,975D
Stock Option (right to buy)26.182026-08-14A · Form 48,952A0[F5]2036-08-13Common Stock8,9528,952D
Performance Stock Option (right to buy)26.182026-08-14A · Form 429,159A0[F6]2036-08-13Common Stock29,15929,159D
Performance Stock Units02026-08-14M · Form 45,233A0[F7]2027-12-31Common Stock5,23341,452D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct
M · Form 4
Exempt derivative exercise or conversion under Rule 16b-3

Footnotes

F1
On May 15, 2026, the third tranche of 5,233 performance stock units ("PSUs") awarded to the Reporting Person under the 2025 PSU Program in connection with her new hire grant vested, of which 2,662 shares were withheld to satisfy taxes.↩ 1
F2
Each restricted stock unit ("RSU") represents the right to receive one share of STAAR Surgical Company ("Company") common stock upon vesting.↩ 1
F3
The Reporting Person was granted Company RSUs on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
F4
The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
F5
The Reporting Person was granted an option to purchase 8,952 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installment thereafter.↩ 1
F6
The Reporting Person was granted a performance option to purchase 29,159 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.↩ 1
F7
Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.↩ 1

Signature 1

Signed
/s/ Deborah Andrews
Date
2026-08-18

Company context

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure.

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding STAAR SURGICAL CONov 16, 2026
  2. 10-Q filingNov 4, 2026
  3. Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 5, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 10, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.